Tags: Life Sciences
EU harmonizes THC limits in hemp seed (food) as from 1 January 2023 – Update Belgium
The EU regulator has harmonized the maximum levels for tetrahydrocannabinol (THC) in hemp seeds throughout the Union within the food contaminants framework.
EU passes sweeping due diligence rules on deforestation-free supply chains for products such as cocoa, coffee and soy
An EU Regulation on the making available on the Union market as well as export from the Union of certain commodities and products associated with deforestation and forest degradation (“Deforestation Regulation”) was agreed upon by the EU legislators in December 2022. The European Parliament has now green-lighted the Provisional Agreement at this month’s plenary session.
ALTIUS Seminars – Pharma Law Seminar
This year, we have the honour of welcoming Wouter Beke (Member of Parliament for CD&V and former Flemish Minister for Welfare, Public Health, Family and Poverty Reduction) and Nick Van Gelder (Head of the Legislation and Litigation Division at the FAGG/AFMPS) as our guest speakers.
WEBINAR VIDEO | The N°1, healthy, rich in learning webinar about claims
During this session, Mathieu Maniet, François Lambert and Karel Martens discuss the rules for No. 1 claims, cosmetic claims and health and nutrition claims, and give you an overview of the most important issues as well as practical guidelines.
The N°1, healthy, rich in learning webinar about claims
Is your product a No.1 seller? Good for your health or rich in fiber? Does it contain no parabens? Do you want to shout it loudly from the rooftops or at least on your packaging?
New Mdeon rules applicable as from 1 January 2023
Mdeon, the legally recognised Belgian ethical platform for healthcare professionals and the pharmaceutical industry, announced several new ethics rules applying from 1 January 2023.
The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines
On 23 January 2018, the European Court of Justice (“ECJ”) handed down its judgment (C-179/16) in relation to Novartis’ Lucentis® and Roche’s Avastin® eye disease medicines, and ruled that disseminating misleading information on the off-label use of a medicine could constitute a restriction of competition ‘by object’.
When are IP holders liable for enforcing a later invalidated IP right?
At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.
WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team will discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO
Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.
WEBINAR VIDEO | Life Sciences Session #9: Hot topics in healthcare tendering
Please join us on 28 November 2022 from 13:30 to 14:30 for our ninth online Life Sciences Session, where Caroline De Mulder and Kirian Claeyé will discuss the latest evolutions in the field of healthcare public procurement and will answer questions such as: